The Use of miRNAs as Chemosensitizing Agents
Location
Atrium
Session Format
Poster Presentation
Research Area Topic:
Public Health & Well Being - Epidemiologic Research
Abstract
Platinum-based drugs are some of the more prominent chemotherapy drugs used in clinical settings. There has been strong evidence to support the use of such drugs with very promising results in many cancers such as lung, testicular, breast and ovarian. However, a small percentage of the population will develop drug resistant forms of these cancers and require a higher dosage of chemotherapy drugs such as cisplatin. These higher doses do not come without side effects, specifically nephrotoxic side effects. There is increasing evidence implicating misregulation of miRNAs in p53-mediated drug resistance. While specific miRNAs are known to participate in feedback loops of p53:MDM2 function, miRNA conservation among multiple cancer cell lines has yet to be assessed. The goal of this research is to attempt to use miRNA and through transfection, down-regulate MDM2, in hopes of sensitizing the cell line to the cisplatin treatment.
Keywords
Chemotherapy, Ovarian, Cancer, Cisplatin, miRNA, p53, MDM2
Presentation Type and Release Option
Presentation (Open Access)
Start Date
4-24-2015 2:45 PM
End Date
4-24-2015 4:00 PM
Recommended Citation
Burleson, Chad E., "The Use of miRNAs as Chemosensitizing Agents" (2015). GS4 Georgia Southern Student Scholars Symposium. 135.
https://digitalcommons.georgiasouthern.edu/research_symposium/2015/2015/135
The Use of miRNAs as Chemosensitizing Agents
Atrium
Platinum-based drugs are some of the more prominent chemotherapy drugs used in clinical settings. There has been strong evidence to support the use of such drugs with very promising results in many cancers such as lung, testicular, breast and ovarian. However, a small percentage of the population will develop drug resistant forms of these cancers and require a higher dosage of chemotherapy drugs such as cisplatin. These higher doses do not come without side effects, specifically nephrotoxic side effects. There is increasing evidence implicating misregulation of miRNAs in p53-mediated drug resistance. While specific miRNAs are known to participate in feedback loops of p53:MDM2 function, miRNA conservation among multiple cancer cell lines has yet to be assessed. The goal of this research is to attempt to use miRNA and through transfection, down-regulate MDM2, in hopes of sensitizing the cell line to the cisplatin treatment.
